Lupin has received final approval for its Fluocinonide Topical Ointment USP, 0.05% from the United States Food and Drug Administration (USFDA) to market a generic version of County Line Pharmaceuticals, LLC’s Lidex Ointment, 0.05%. Lidex Ointment had US sales of $40.3 million, as per IMS MAT March 2017.
Lupin’s Fluocinonide Topical Ointment USP, 0.05% is AB rated generic equivalent of County Line Pharmaceuticals, LLC’s Lidex Ointment, 0.05%. It is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.
